<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819585</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885H2251</org_study_id>
    <secondary_id>EudraCT : 2008-005876-28</secondary_id>
    <nct_id>NCT00819585</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)</brief_title>
  <official_title>A 24-week, Dose-ranging, Multicenter, Double-blind, Double-dummy, Active-controlled Core Study to Evaluate Canakinumab for Prophylaxis of Signs and Symptoms of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy and a 24-week Open-label, Multicenter Extension Study to Assess Safety, Tolerability and Efficacy of Canakinumab in Patients With Gout Who Are Given Canakinumab at the Time of Gout Flare</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core
      study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute
      flares in chronic gout patients initiating allopurinol therapy. The core study was followed
      by a 24-week open-label, multicenter extension study to assess the safety, tolerability, and
      efficacy of canakinumab in patients with gout who were given canakinumab at the time of gout
      flare.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Core Study: Mean Number of Gout Flares Per Participant</measure>
    <time_frame>Baseline of the core study to Week 16</time_frame>
    <description>A gout flare was defined as an increase in participant-reported gout pain in the most affected joint during a gout attack.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Core Study: Mean Number of Gout Flares for the Repeat Dose Regimen of Canakinumab as Compared to the Single Doses of Canakinumab</measure>
    <time_frame>up to 16 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Percentage of Participants With at Least 1 Gout Flare Within 16 Weeks After Randomization</measure>
    <time_frame>Baseline of the core study to Week 16</time_frame>
    <description>The percentage of participants experiencing at least 1 gout flare within 16 weeks after randomization. A gout flare was defined as an increase in participant-reported gout pain in the most affected joint during a gout attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Percentage of Participants With Gout Flare at Different Time Points</measure>
    <time_frame>Days 2, 4, 6, and Weeks 2, 4, 6, 10, and 16 of the core study</time_frame>
    <description>A gout flare was defined as an increase in participant-reported gout pain in the most affected joint during a gout attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Participant's Assessment of Gout Pain on a 0-100 mm Visual Analog Scale up to Day 7 of All Gout Flares</measure>
    <time_frame>Baseline of the core study to Week 16</time_frame>
    <description>Participants rated the intensity of pain in the most affected joint on a 0-100 mm visual analog scale, which ranged from no pain (left end, 0) to unbearable pain (right end, 100). Participants assessed pain intensity on the day of onset of the gout flare and in the morning of the 6 following days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Participant's Assessment of Gout Pain on a 5-point Likert Scale up to Day 7 of All Gout Flares</measure>
    <time_frame>Baseline of the core study to Week 16</time_frame>
    <description>Participants assessed the intensity of pain in the most affected joint on a 5-point Likert scale, which ranged from 1 to 5 (1=None, 2=Mild, 3=Moderate, 4=Severe, 5=Extreme). Participants assessed pain intensity on the day of onset of the gout flare and in the morning of the 6 following days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Study: Physician's Global Assessment of Response to Therapy on a 5-point Likert Scale</measure>
    <time_frame>Days 15, 29, 57, 85, 113, and 141 of the core study</time_frame>
    <description>The study physician made a global assessment of the participant's response to treatment on a 5-point Likert scale (Very good, Good, Fair, Poor, Very poor) at Days 15, 29, 57, 85, 113, and 141. The category 'Not assessed' includes missing data and 'not done'. The number of participants in each of the 5 categories of the Likert scale are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Participant's Assessment of Gout Pain on a 100 mm Visual Analog Scale During the First Flare</measure>
    <time_frame>Baseline of the extension study until 7 days after the onset of the first gout flare (up to 24 weeks)</time_frame>
    <description>Participant's rated the intensity of pain in the most affected joint during the first flare on a 0-100 mm visual analog scale, which ranged from no pain (left end, 0) to unbearable pain (right end, 100). Assessments were made pre-dose and 24 hours, 3 days, 4 days, and an average of 5-7 days post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Participant's Global Assessment of Response to Treatment on a 5-point Likert Scale</measure>
    <time_frame>Baseline of the extension study until the end of the study (up to 24 weeks)</time_frame>
    <description>Study participants made a global assessment of their response to treatment on a 5-point Likert scale (Excellent, Good, Acceptable, Slight, Poor) at the control visit 7±2 days following each of their first 3 flares. The number of participants in each of the 5 categories of the Likert scale are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Physician's Global Assessment of Response to Treatment on a 5-point Likert Scale</measure>
    <time_frame>Baseline of the extension study until the end of the study (up to 24 weeks)</time_frame>
    <description>The study physician made a global assessment of the participant's response to treatment on a 5-point Likert scale (Very good, Good, Fair, Poor, Very poor) at the control visit 7±2 days following each of the first 3 flares. The category 'Not assessed' includes missing data and 'not done'. The number of participants in each of the 5 categories of the Likert scale are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Physician's Assessment of Tenderness, Swelling, and Erythema in the Most Affected Joint During the First Flare</measure>
    <time_frame>Baseline of the extension study until the end of the study (up to 24 weeks)</time_frame>
    <description>Tenderness was rated on a 0-3 point scale: 0=&quot;no pain&quot;, 1=patient states that &quot;there is pain&quot;, 2=patient states &quot;there is pain and winces&quot;, and 3=patient states &quot;there is pain, winces and withdraws&quot; on palpation or passive movement of the most affected joint. Swelling was rated on a 0-3 point scale: 0=&quot;no swelling&quot;, 1=&quot;palpable&quot;, 2=&quot;visible&quot;, and 3=bulging beyond the joint margins&quot;. Erythema was rated as present, absent, or not assessable. Assessments were performed at the flare and control visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Study: Amount of Rescue Medication Taken</measure>
    <time_frame>Baseline of the extension study until the end of the study (up to 24 weeks)</time_frame>
    <description>The amount of naproxen and prednisolone taken after receiving treatment for each of the first 3 flares was recorded.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">432</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Core study: Canakinumab 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Canakinumab 25 mg subcutaneously (sc) once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core study: Canakinumab 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Canakinumab 50 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core study: Canakinumab 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core study: Canakinumab 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core study: Canakinumab 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Canakinumab 300 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core study: Canakinumab q4wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Canakinumab 50 mg sc at Days 1, and 29 followed by canakinumab 25 mg sc on Days 57, and 85 plus daily placebo capsules for 16 weeks, repeated every 4 week (q4wk). Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Core study: Colchicine 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.5 mg capsule orally once daily throughout the whole treatment phase of 16 weeks plus placebo matching canakinumab s.c. at Days 1, 29, 57, and 85. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension study: Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension study: Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were randomized to canakinumab in the core study but did not receive treatment with canakinumab in the extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension study: Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension study: Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were randomized to colchicine in the core study but did not receive treatment with canakinumab in the extension study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <description>Canakinumab was supplied in glass vials as a lyophilized powder.</description>
    <arm_group_label>Core study: Canakinumab 100 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 200 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 25 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 300 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 50 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab q4wk</arm_group_label>
    <arm_group_label>Extension study: Group A</arm_group_label>
    <arm_group_label>Extension study: Group B</arm_group_label>
    <arm_group_label>Extension study: Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>0.5 mg capsule orally once daily for 16 weeks.</description>
    <arm_group_label>Core study: Colchicine 0.5 mg</arm_group_label>
    <arm_group_label>Extension study: Group C</arm_group_label>
    <arm_group_label>Extension study: Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>100-300 mg orally once daily for 24 weeks.</description>
    <arm_group_label>Core study: Canakinumab 100 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 200 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 25 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 300 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 50 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab q4wk</arm_group_label>
    <arm_group_label>Core study: Colchicine 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Matching Canakinumab</intervention_name>
    <description>Subcutaneous injection.</description>
    <arm_group_label>Core study: Canakinumab 100 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 200 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 25 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 300 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 50 mg</arm_group_label>
    <arm_group_label>Core study: Colchicine 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Matching Colchicine</intervention_name>
    <description>Capsule orally once daily for 16 weeks.</description>
    <arm_group_label>Core study: Canakinumab 100 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 200 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 25 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 300 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab 50 mg</arm_group_label>
    <arm_group_label>Core study: Canakinumab q4wk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Core study

        Inclusion Criteria:

          -  Signed written informed consent before any study procedure is performed.

          -  History of at least 2 gout flares in the year prior to Screening (Visit 1, based on
             patient history), thus, candidates for initiating uric acid lowering therapy.

          -  Confirmed diagnosis of gout meeting the American College of Rheumatology (ACR) 1977
             preliminary criteria for the classification of arthritis of primary gout.

          -  Body Mass Index (BMI) ≤ 40 kg/m^2.

          -  Willingness to initiate allopurinol therapy as urate lowering agent for their gout
             therapy or having initiated allopurinol therapy within ≤ 1 month before Screening
             (Visit 1) or willing to re-initiate allopurinol therapy if this was stopped &gt; 2 months
             before Screening (Visit 1) for reasons different to toxicity/ intolerance or lack of
             efficacy.

        Exclusion Criteria:

          -  Acute gout flare within 2 weeks of Screening (Visit 1) and during the Screening
             period.

          -  History of allergy or contraindication to colchicine or allopurinol.

          -  History of intolerance to allopurinol or to oral colchicine in appropriate dose for
             prophylactic use.

          -  History of bone marrow suppression.

          -  Absolute or relative contraindication to both naproxen and oral prednisolone/
             prednisone.

        Extension study

        Inclusion criteria:

          -  Patients who completed the core study. A patient is defined as completing the core
             study if he/she completed the study up to and including the last visit (Visit 9).

          -  Patients who have signed a written informed consent before any trial procedure is
             performed.

        Exclusion Criteria:

          -  Patients for whom continuation in the extension study is not considered appropriate by
             the treating physician.

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive pregnancy test (serum or urine).

        Other protocol-defined inclusion/exclusion criteria applied to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Talbert Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Arthritis &amp; Osteoporosis Medical clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Medical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinical Research Institute</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolby Research, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Family Doctors</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shores Rheumatology</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Clinical Research, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NM Clinical Research &amp; Osteoporosis Ct.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma, PLLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castlerock Clinical Research Consultants, LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Clinical Research</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Pharmaceutical Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiSpecialty Clinical Research</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iMED Internal medicine, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gozée</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Oostham</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bacaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Cardiovascular de Colombia</name>
      <address>
        <city>Florida Blanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Havirov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bautzen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Georgensgmuend</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goettingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messkirch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riedlhuette</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwabach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kistarcsa</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Ponte de Lima</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Piestany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Trebisova</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Panorama</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Merida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baskent University Medical Faculty</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baskent University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adnan Menderes University Medical Faculty</name>
      <address>
        <city>Aydin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova University Medical Faculty</name>
      <address>
        <city>Balcali Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamukkale University medical Faculty</name>
      <address>
        <city>Denizli Kampus</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaziantep University Medical Faculty</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celal Bayar University Medical Faculty</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gables Medicentre</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flyde Coast Clinical Research Ltd</name>
      <address>
        <city>Lancashire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <results_first_submitted>February 28, 2011</results_first_submitted>
  <results_first_submitted_qc>April 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2011</results_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Chronic gout</keyword>
  <keyword>Gouty arthritis</keyword>
  <keyword>Gout flares</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 432 participants were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Core Study: Canakinumab 25 mg</title>
          <description>Participants received canakinumab 25 mg subcutaneously (sc) on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Core Study: Canakinumab 50 mg</title>
          <description>Participants received canakinumab 50 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Core Study: Canakinumab 100 mg</title>
          <description>Participants received canakinumab 100 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Core Study: Canakinumab 200 mg</title>
          <description>Participants received canakinumab 200 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Core Study: Canakinumab 300 mg</title>
          <description>Participants received canakinumab 300 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Core Study: Canakinumab q4wk</title>
          <description>Participants received canakinumab 50 mg sc on Days 1 and 29; canakinumab 25 mg sc on Days 57 and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Core Study: Colchicine 0.5 mg</title>
          <description>Participants received colchicine 0.5 mg orally once daily for 16 weeks and canakinumab placebo sc on Days 1, 29, 57, and 85.</description>
        </group>
        <group group_id="P8">
          <title>Extension Study: Group A</title>
          <description>Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
        </group>
        <group group_id="P9">
          <title>Extension Study: Group B</title>
          <description>Patients who were randomized to canakinumab in the core study but did not receive treatment with canakinumab in the extension study.</description>
        </group>
        <group group_id="P10">
          <title>Extension Study: Group C</title>
          <description>Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
        </group>
        <group group_id="P11">
          <title>Extension Study: Group D</title>
          <description>Patients who were randomized to colchicine in the core study but did not receive treatment with canakinumab in the extension study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55">Participants who started the core study are included in the randomized and full analysis sets.</participants>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="53"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="108"/>
                <participants group_id="P8" count="0">There were no participants in this arm during the core study.</participants>
                <participants group_id="P9" count="0">There were no participants in this arm during the core study.</participants>
                <participants group_id="P10" count="0">There were no participants in this arm during the core study.</participants>
                <participants group_id="P11" count="0">There were no participants in this arm during the core study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="55">Participants who received study medication are included in the safety population.</participants>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="53"/>
                <participants group_id="P6" count="53">One participant in this treatment arm was HIV+ve and did not receive any study medication.</participants>
                <participants group_id="P7" count="108"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="95"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Laboratory Value(s)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Therapeutic Effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject No Longer Requires Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">There were no participants in this arm during the extension study.</participants>
                <participants group_id="P2" count="0">There were no participants in this arm during the extension study.</participants>
                <participants group_id="P3" count="0">There were no participants in this arm during the extension study.</participants>
                <participants group_id="P4" count="0">There were no participants in this arm during the extension study.</participants>
                <participants group_id="P5" count="0">There were no participants in this arm during the extension study.</participants>
                <participants group_id="P6" count="0">There were no participants in this arm during the extension study.</participants>
                <participants group_id="P7" count="0">There were no participants in this arm during the extension study.</participants>
                <participants group_id="P8" count="75"/>
                <participants group_id="P9" count="181"/>
                <participants group_id="P10" count="25"/>
                <participants group_id="P11" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="75"/>
                <participants group_id="P9" count="173"/>
                <participants group_id="P10" count="24"/>
                <participants group_id="P11" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Abnormal Laboratory Value(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Baseline Characteristics of the reporting groups are based on the safety set, which included all participants who received study medication. Of the 432 participants enrolled in the core study, 1 participant did not receive any study medication and was not included in the safety set.</population>
      <group_list>
        <group group_id="B1">
          <title>Core Study: Canakinumab 25 mg</title>
          <description>Participants received canakinumab 25 mg subcutaneously (sc) on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Core Study: Canakinumab 50 mg</title>
          <description>Participants received canakinumab 50 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Core Study: Canakinumab 100 mg</title>
          <description>Participants received canakinumab 100 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Core Study: Canakinumab 200 mg</title>
          <description>Participants received canakinumab 200 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Core Study: Canakinumab 300 mg</title>
          <description>Participants received canakinumab 300 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Core Study: Canakinumab q4wk</title>
          <description>Participants received canakinumab 50 mg sc on Days 1 and 29; canakinumab 25 mg sc on Days 57 and 85; and colchicine placebo orally once daily for 16 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Core Study: Colchicine 0.5 mg</title>
          <description>Participants received colchicine 0.5 mg orally once daily for 16 weeks and canakinumab placebo sc on Days 1, 29, 57, and 85.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="54"/>
            <count group_id="B5" value="53"/>
            <count group_id="B6" value="53"/>
            <count group_id="B7" value="108"/>
            <count group_id="B8" value="431"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="9.72"/>
                    <measurement group_id="B2" value="54.4" spread="12.18"/>
                    <measurement group_id="B3" value="51.3" spread="12.41"/>
                    <measurement group_id="B4" value="52.6" spread="10.78"/>
                    <measurement group_id="B5" value="52.4" spread="11.30"/>
                    <measurement group_id="B6" value="52.8" spread="10.38"/>
                    <measurement group_id="B7" value="52.4" spread="10.69"/>
                    <measurement group_id="B8" value="52.4" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="101"/>
                    <measurement group_id="B8" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Mean Number of Gout Flares for the Repeat Dose Regimen of Canakinumab as Compared to the Single Doses of Canakinumab</title>
        <time_frame>up to 16 weeks after randomization</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab 25 mg</title>
            <description>Canakinumab 25 mg subcutaneously (s.c.) once at Day 1, placebo s.c. at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg- 300 mg) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canakinumab 50 mg</title>
            <description>Canakinumab 50 mg s.c. once at Day 1, placebo s.c. at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg- 300 mg) for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canakinumab 100 mg</title>
            <description>Canakinumab 100 mg s.c. once at Day 1, placebo s.c. at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg- 300 mg) for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Canakinumab 200 mg</title>
            <description>Canakinumab 200 mg s.c. once at Day 1, placebo s.c. at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg- 300 mg) for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Canakinumab 300 mg</title>
            <description>Canakinumab 300 mg s.c. once at Day 1, placebo s.c. at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg- 300 mg) for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Canakinumab q4wk</title>
            <description>Canakinumab 50 mg s.c. at Days 1, and 29 followed by canakinumab 25 mg s.c. on Days 57, and 85 plus daily placebo capsules for 16 weeks, repeated every 4 week (q4wk). Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg- 300 mg) for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Mean Number of Gout Flares for the Repeat Dose Regimen of Canakinumab as Compared to the Single Doses of Canakinumab</title>
          <population>The Full Analysis Set (FAS) consisted of all patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization.</population>
          <units>gout flares per patient</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.204"/>
                    <measurement group_id="O2" value="0.43" spread="0.207"/>
                    <measurement group_id="O3" value="0.22" spread="0.209"/>
                    <measurement group_id="O4" value="0.38" spread="0.205"/>
                    <measurement group_id="O5" value="0.21" spread="0.209"/>
                    <measurement group_id="O6" value="0.68" spread="0.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Percentage of Participants With at Least 1 Gout Flare Within 16 Weeks After Randomization</title>
        <description>The percentage of participants experiencing at least 1 gout flare within 16 weeks after randomization. A gout flare was defined as an increase in participant-reported gout pain in the most affected joint during a gout attack.</description>
        <time_frame>Baseline of the core study to Week 16</time_frame>
        <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Study: Canakinumab 25 mg</title>
            <description>Participants received canakinumab 25 mg subcutaneously (sc) on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Study: Canakinumab 50 mg</title>
            <description>Participants received canakinumab 50 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Study: Canakinumab 100 mg</title>
            <description>Participants received canakinumab 100 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Study: Canakinumab 200 mg</title>
            <description>Participants received canakinumab 200 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Study: Canakinumab 300 mg</title>
            <description>Participants received canakinumab 300 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Study: Canakinumab q4wk</title>
            <description>Participants received canakinumab 50 mg sc on Days 1 and 29; canakinumab 25 mg sc on Days 57 and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Core Study: Colchicine 0.5 mg</title>
            <description>Participants received colchicine 0.5 mg orally once daily for 16 weeks and canakinumab placebo sc on Days 1, 29, 57, and 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Percentage of Participants With at Least 1 Gout Flare Within 16 Weeks After Randomization</title>
          <description>The percentage of participants experiencing at least 1 gout flare within 16 weeks after randomization. A gout flare was defined as an increase in participant-reported gout pain in the most affected joint during a gout attack.</description>
          <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="14.8"/>
                    <measurement group_id="O4" value="18.5"/>
                    <measurement group_id="O5" value="15.1"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Percentage of Participants With Gout Flare at Different Time Points</title>
        <description>A gout flare was defined as an increase in participant-reported gout pain in the most affected joint during a gout attack.</description>
        <time_frame>Days 2, 4, 6, and Weeks 2, 4, 6, 10, and 16 of the core study</time_frame>
        <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Study: Canakinumab 25 mg</title>
            <description>Participants received canakinumab 25 mg subcutaneously (sc) on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Study: Canakinumab 50 mg</title>
            <description>Participants received canakinumab 50 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Study: Canakinumab 100 mg</title>
            <description>Participants received canakinumab 100 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Study: Canakinumab 200 mg</title>
            <description>Participants received canakinumab 200 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Study: Canakinumab 300 mg</title>
            <description>Participants received canakinumab 300 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Study: Canakinumab q4wk</title>
            <description>Participants received canakinumab 50 mg sc on Days 1 and 29; canakinumab 25 mg sc on Days 57 and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Core Study: Colchicine 0.5 mg</title>
            <description>Participants received colchicine 0.5 mg orally once daily for 16 weeks and canakinumab placebo sc on Days 1, 29, 57, and 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Percentage of Participants With Gout Flare at Different Time Points</title>
          <description>A gout flare was defined as an increase in participant-reported gout pain in the most affected joint during a gout attack.</description>
          <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 days post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="1.79" upper_limit="15.96"/>
                    <measurement group_id="O2" value="3.7" lower_limit="0.94" upper_limit="14.01"/>
                    <measurement group_id="O3" value="3.7" lower_limit="0.94" upper_limit="14.01"/>
                    <measurement group_id="O4" value="3.7" lower_limit="0.94" upper_limit="14.01"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="3.8" lower_limit="0.96" upper_limit="14.26"/>
                    <measurement group_id="O7" value="5.6" lower_limit="2.53" upper_limit="11.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 days post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="5.05" upper_limit="22.68"/>
                    <measurement group_id="O2" value="3.7" lower_limit="0.94" upper_limit="14.01"/>
                    <measurement group_id="O3" value="3.7" lower_limit="0.94" upper_limit="14.01"/>
                    <measurement group_id="O4" value="3.7" lower_limit="0.94" upper_limit="14.01"/>
                    <measurement group_id="O5" value="5.7" lower_limit="1.86" upper_limit="16.53"/>
                    <measurement group_id="O6" value="3.8" lower_limit="0.96" upper_limit="14.26"/>
                    <measurement group_id="O7" value="10.2" lower_limit="5.77" upper_limit="17.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 days post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="6.28" upper_limit="24.85"/>
                    <measurement group_id="O2" value="5.6" lower_limit="1.83" upper_limit="16.24"/>
                    <measurement group_id="O3" value="3.7" lower_limit="0.94" upper_limit="14.01"/>
                    <measurement group_id="O4" value="7.4" lower_limit="2.85" upper_limit="18.54"/>
                    <measurement group_id="O5" value="5.7" lower_limit="1.86" upper_limit="16.53"/>
                    <measurement group_id="O6" value="3.8" lower_limit="0.96" upper_limit="23.56"/>
                    <measurement group_id="O7" value="11.1" lower_limit="6.47" upper_limit="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="7.55" upper_limit="26.99"/>
                    <measurement group_id="O2" value="7.4" lower_limit="2.85" upper_limit="18.54"/>
                    <measurement group_id="O3" value="7.4" lower_limit="2.85" upper_limit="18.54"/>
                    <measurement group_id="O4" value="11.1" lower_limit="5.15" upper_limit="23.07"/>
                    <measurement group_id="O5" value="7.5" lower_limit="2.90" upper_limit="18.87"/>
                    <measurement group_id="O6" value="11.3" lower_limit="5.25" upper_limit="23.48"/>
                    <measurement group_id="O7" value="16.7" lower_limit="10.85" upper_limit="25.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="7.55" upper_limit="26.99"/>
                    <measurement group_id="O2" value="9.3" lower_limit="3.96" upper_limit="20.83"/>
                    <measurement group_id="O3" value="7.4" lower_limit="2.85" upper_limit="18.54"/>
                    <measurement group_id="O4" value="13.0" lower_limit="6.40" upper_limit="25.28"/>
                    <measurement group_id="O5" value="11.4" lower_limit="5.27" upper_limit="23.56"/>
                    <measurement group_id="O6" value="15.1" lower_limit="7.85" upper_limit="27.92"/>
                    <measurement group_id="O7" value="25.1" lower_limit="17.93" upper_limit="34.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="8.96" upper_limit="29.39"/>
                    <measurement group_id="O2" value="11.1" lower_limit="5.15" upper_limit="23.07"/>
                    <measurement group_id="O3" value="9.3" lower_limit="3.98" upper_limit="20.91"/>
                    <measurement group_id="O4" value="13.0" lower_limit="6.40" upper_limit="25.28"/>
                    <measurement group_id="O5" value="11.4" lower_limit="5.27" upper_limit="23.56"/>
                    <measurement group_id="O6" value="27.92" lower_limit="7.85" upper_limit="27.92"/>
                    <measurement group_id="O7" value="32.6" lower_limit="24.58" upper_limit="42.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 weeks post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="13.43" upper_limit="36.26"/>
                    <measurement group_id="O2" value="13.1" lower_limit="6.46" upper_limit="25.52"/>
                    <measurement group_id="O3" value="11.2" lower_limit="5.19" upper_limit="23.22"/>
                    <measurement group_id="O4" value="16.8" lower_limit="9.11" upper_limit="29.79"/>
                    <measurement group_id="O5" value="11.4" lower_limit="5.27" upper_limit="23.56"/>
                    <measurement group_id="O6" value="17.0" lower_limit="9.22" upper_limit="30.09"/>
                    <measurement group_id="O7" value="37.5" lower_limit="29.06" upper_limit="47.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="18.34" upper_limit="43.10"/>
                    <measurement group_id="O2" value="17.3" lower_limit="9.37" upper_limit="30.66"/>
                    <measurement group_id="O3" value="15.1" lower_limit="7.82" upper_limit="27.87"/>
                    <measurement group_id="O4" value="18.8" lower_limit="10.59" upper_limit="32.19"/>
                    <measurement group_id="O5" value="15.3" lower_limit="7.96" upper_limit="28.29"/>
                    <measurement group_id="O6" value="17.0" lower_limit="9.22" upper_limit="30.09"/>
                    <measurement group_id="O7" value="45.8" lower_limit="36.76" upper_limit="55.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Participant's Assessment of Gout Pain on a 0-100 mm Visual Analog Scale up to Day 7 of All Gout Flares</title>
        <description>Participants rated the intensity of pain in the most affected joint on a 0-100 mm visual analog scale, which ranged from no pain (left end, 0) to unbearable pain (right end, 100). Participants assessed pain intensity on the day of onset of the gout flare and in the morning of the 6 following days.</description>
        <time_frame>Baseline of the core study to Week 16</time_frame>
        <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Study: Canakinumab 25 mg</title>
            <description>Participants received canakinumab 25 mg subcutaneously (sc) on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Study: Canakinumab 50 mg</title>
            <description>Participants received canakinumab 50 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Study: Canakinumab 100 mg</title>
            <description>Participants received canakinumab 100 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Study: Canakinumab 200 mg</title>
            <description>Participants received canakinumab 200 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Study: Canakinumab 300 mg</title>
            <description>Participants received canakinumab 300 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Study: Canakinumab q4wk</title>
            <description>Participants received canakinumab 50 mg sc on Days 1 and 29; canakinumab 25 mg sc on Days 57 and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Core Study: Colchicine 0.5 mg</title>
            <description>Participants received colchicine 0.5 mg orally once daily for 16 weeks and canakinumab placebo sc on Days 1, 29, 57, and 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Participant's Assessment of Gout Pain on a 0-100 mm Visual Analog Scale up to Day 7 of All Gout Flares</title>
          <description>Participants rated the intensity of pain in the most affected joint on a 0-100 mm visual analog scale, which ranged from no pain (left end, 0) to unbearable pain (right end, 100). Participants assessed pain intensity on the day of onset of the gout flare and in the morning of the 6 following days.</description>
          <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=15, 9, 8, 9, 8, 9, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" spread="31.01"/>
                    <measurement group_id="O2" value="44.6" spread="15.82"/>
                    <measurement group_id="O3" value="56.3" spread="26.72"/>
                    <measurement group_id="O4" value="53.0" spread="27.99"/>
                    <measurement group_id="O5" value="52.2" spread="19.40"/>
                    <measurement group_id="O6" value="66.1" spread="15.07"/>
                    <measurement group_id="O7" value="53.1" spread="24.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n=12, 7, 6, 5, 5, 7, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" spread="30.06"/>
                    <measurement group_id="O2" value="40.1" spread="26.73"/>
                    <measurement group_id="O3" value="46.2" spread="35.11"/>
                    <measurement group_id="O4" value="19.8" spread="32.05"/>
                    <measurement group_id="O5" value="43.1" spread="17.62"/>
                    <measurement group_id="O6" value="59.3" spread="23.53"/>
                    <measurement group_id="O7" value="42.8" spread="24.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=10, 4, 4, 4, 4, 5, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="20.82"/>
                    <measurement group_id="O2" value="49.5" spread="18.48"/>
                    <measurement group_id="O3" value="49.5" spread="25.29"/>
                    <measurement group_id="O4" value="56.7" spread="40.91"/>
                    <measurement group_id="O5" value="26.3" spread="14.64"/>
                    <measurement group_id="O6" value="58.0" spread="27.59"/>
                    <measurement group_id="O7" value="38.1" spread="23.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n=7, 3, 2, 3, 3, 6, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="16.77"/>
                    <measurement group_id="O2" value="46.3" spread="10.60"/>
                    <measurement group_id="O3" value="16.5" spread="23.33"/>
                    <measurement group_id="O4" value="63.5" spread="33.0"/>
                    <measurement group_id="O5" value="11.0" spread="11.0"/>
                    <measurement group_id="O6" value="49.4" spread="27.73"/>
                    <measurement group_id="O7" value="30.5" spread="26.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (n=7, 2, 1, 3, 2, 4, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="14.79"/>
                    <measurement group_id="O2" value="48.0" spread="5.66"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="54.8" spread="43.38"/>
                    <measurement group_id="O5" value="13.0" spread="0.0"/>
                    <measurement group_id="O6" value="41.4" spread="33.63"/>
                    <measurement group_id="O7" value="31.8" spread="29.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n=6, 1, 1, 2, 1, 3, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="14.14"/>
                    <measurement group_id="O2" value="44.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="57.5" spread="60.10"/>
                    <measurement group_id="O5" value="12.0" spread="0.0"/>
                    <measurement group_id="O6" value="43.5" spread="24.38"/>
                    <measurement group_id="O7" value="33.7" spread="26.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=6, 0, 1, 2, 1, 2, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="16.91"/>
                    <measurement group_id="O2" value="NA" spread="NA">No data is available</measurement>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="35.0" spread="49.50"/>
                    <measurement group_id="O5" value="0.0" spread="0.0"/>
                    <measurement group_id="O6" value="52.0" spread="11.31"/>
                    <measurement group_id="O7" value="33.0" spread="22.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Participant's Assessment of Gout Pain on a 5-point Likert Scale up to Day 7 of All Gout Flares</title>
        <description>Participants assessed the intensity of pain in the most affected joint on a 5-point Likert scale, which ranged from 1 to 5 (1=None, 2=Mild, 3=Moderate, 4=Severe, 5=Extreme). Participants assessed pain intensity on the day of onset of the gout flare and in the morning of the 6 following days.</description>
        <time_frame>Baseline of the core study to Week 16</time_frame>
        <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Study: Canakinumab 25 mg</title>
            <description>Participants received canakinumab 25 mg subcutaneously (sc) on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Study: Canakinumab 50 mg</title>
            <description>Participants received canakinumab 50 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Study: Canakinumab 100 mg</title>
            <description>Participants received canakinumab 100 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Study: Canakinumab 200 mg</title>
            <description>Participants received canakinumab 200 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Study: Canakinumab 300 mg</title>
            <description>Participants received canakinumab 300 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Study: Canakinumab q4wk</title>
            <description>Participants received canakinumab 50 mg sc on Days 1 and 29; canakinumab 25 mg sc on Days 57 and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Core Study: Colchicine 0.5 mg</title>
            <description>Participants received colchicine 0.5 mg orally once daily for 16 weeks and canakinumab placebo sc on Days 1, 29, 57, and 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Participant's Assessment of Gout Pain on a 5-point Likert Scale up to Day 7 of All Gout Flares</title>
          <description>Participants assessed the intensity of pain in the most affected joint on a 5-point Likert scale, which ranged from 1 to 5 (1=None, 2=Mild, 3=Moderate, 4=Severe, 5=Extreme). Participants assessed pain intensity on the day of onset of the gout flare and in the morning of the 6 following days.</description>
          <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=15, 8, 8, 9, 8, 9, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.88"/>
                    <measurement group_id="O2" value="3.1" spread="0.65"/>
                    <measurement group_id="O3" value="3.5" spread="1.20"/>
                    <measurement group_id="O4" value="3.2" spread="0.92"/>
                    <measurement group_id="O5" value="3.1" spread="0.35"/>
                    <measurement group_id="O6" value="3.8" spread="0.60"/>
                    <measurement group_id="O7" value="3.2" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n=12, 6, 6, 5, 5, 7, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.92"/>
                    <measurement group_id="O2" value="2.6" spread="1.02"/>
                    <measurement group_id="O3" value="3.3" spread="1.51"/>
                    <measurement group_id="O4" value="2.2" spread="1.10"/>
                    <measurement group_id="O5" value="2.9" spread="0.74"/>
                    <measurement group_id="O6" value="3.5" spread="1.05"/>
                    <measurement group_id="O7" value="3.0" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=10, 4, 4, 4, 4, 6, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.73"/>
                    <measurement group_id="O2" value="3.1" spread="0.63"/>
                    <measurement group_id="O3" value="2.3" spread="0.96"/>
                    <measurement group_id="O4" value="3.0" spread="1.15"/>
                    <measurement group_id="O5" value="2.3" spread="0.50"/>
                    <measurement group_id="O6" value="3.4" spread="1.07"/>
                    <measurement group_id="O7" value="2.7" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n=7, 3, 2, 3, 3, 7, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.57"/>
                    <measurement group_id="O2" value="2.7" spread="0.58"/>
                    <measurement group_id="O3" value="1.5" spread="0.71"/>
                    <measurement group_id="O4" value="3.0" spread="1.00"/>
                    <measurement group_id="O5" value="1.7" spread="0.58"/>
                    <measurement group_id="O6" value="3.2" spread="1.08"/>
                    <measurement group_id="O7" value="2.4" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (n=7, 2, 1, 3, 2, 4, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.69"/>
                    <measurement group_id="O2" value="2.5" spread="0.71"/>
                    <measurement group_id="O3" value="1.0" spread="0"/>
                    <measurement group_id="O4" value="3.2" spread="1.76"/>
                    <measurement group_id="O5" value="1.5" spread="0.71"/>
                    <measurement group_id="O6" value="2.7" spread="1.28"/>
                    <measurement group_id="O7" value="2.6" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n=6, 1, 1, 2, 2, 3, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.49"/>
                    <measurement group_id="O2" value="3.0" spread="0.0"/>
                    <measurement group_id="O3" value="1.0" spread="0.0"/>
                    <measurement group_id="O4" value="3.5" spread="2.12"/>
                    <measurement group_id="O5" value="1.5" spread="0.71"/>
                    <measurement group_id="O6" value="2.9" spread="0.84"/>
                    <measurement group_id="O7" value="2.5" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=6, 0, 1, 2, 1, 2, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.49"/>
                    <measurement group_id="O2" value="NA" spread="NA">No participants analyzed.</measurement>
                    <measurement group_id="O3" value="1.0" spread="0.0"/>
                    <measurement group_id="O4" value="2.5" spread="2.12"/>
                    <measurement group_id="O5" value="1.0" spread="0.0"/>
                    <measurement group_id="O6" value="3.3" spread="0.47"/>
                    <measurement group_id="O7" value="2.4" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Core Study: Mean Number of Gout Flares Per Participant</title>
        <description>A gout flare was defined as an increase in participant-reported gout pain in the most affected joint during a gout attack.</description>
        <time_frame>Baseline of the core study to Week 16</time_frame>
        <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Study: Canakinumab 25 mg</title>
            <description>Participants received canakinumab 25 mg subcutaneously (sc) on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Study: Canakinumab 50 mg</title>
            <description>Participants received canakinumab 50 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Study: Canakinumab 100 mg</title>
            <description>Participants received canakinumab 100 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Study: Canakinumab 200 mg</title>
            <description>Participants received canakinumab 200 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Study: Canakinumab 300 mg</title>
            <description>Participants received canakinumab 300 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Study: Canakinumab q4wk</title>
            <description>Participants received canakinumab 50 mg sc on Days 1 and 29; canakinumab 25 mg sc on Days 57 and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Core Study: Colchicine 0.5 mg</title>
            <description>Participants received colchicine 0.5 mg orally once daily for 16 weeks and canakinumab placebo sc on Days 1, 29, 57, and 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Mean Number of Gout Flares Per Participant</title>
          <description>A gout flare was defined as an increase in participant-reported gout pain in the most affected joint during a gout attack.</description>
          <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
          <units>Gout flares</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.03"/>
                    <measurement group_id="O2" value="0.4" spread="1.82"/>
                    <measurement group_id="O3" value="0.2" spread="0.53"/>
                    <measurement group_id="O4" value="0.4" spread="1.35"/>
                    <measurement group_id="O5" value="0.2" spread="0.53"/>
                    <measurement group_id="O6" value="0.7" spread="2.24"/>
                    <measurement group_id="O7" value="0.7" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Study: Physician's Global Assessment of Response to Therapy on a 5-point Likert Scale</title>
        <description>The study physician made a global assessment of the participant's response to treatment on a 5-point Likert scale (Very good, Good, Fair, Poor, Very poor) at Days 15, 29, 57, 85, 113, and 141. The category 'Not assessed' includes missing data and 'not done'. The number of participants in each of the 5 categories of the Likert scale are reported.</description>
        <time_frame>Days 15, 29, 57, 85, 113, and 141 of the core study</time_frame>
        <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Core Study: Canakinumab 25 mg</title>
            <description>Participants received canakinumab 25 mg subcutaneously (sc) on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Core Study: Canakinumab 50 mg</title>
            <description>Participants received canakinumab 50 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Core Study: Canakinumab 100 mg</title>
            <description>Participants received canakinumab 100 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Core Study: Canakinumab 200 mg</title>
            <description>Participants received canakinumab 200 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Core Study: Canakinumab 300 mg</title>
            <description>Participants received canakinumab 300 mg sc on Day 1; canakinumab placebo sc on Days 29, 57, and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Core Study: Canakinumab q4wk</title>
            <description>Participants received canakinumab 50 mg sc on Days 1 and 29; canakinumab 25 mg sc on Days 57 and 85; and colchicine placebo orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Core Study: Colchicine 0.5 mg</title>
            <description>Participants received colchicine 0.5 mg orally once daily for 16 weeks and canakinumab placebo sc on Days 1, 29, 57, and 85.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Study: Physician's Global Assessment of Response to Therapy on a 5-point Likert Scale</title>
          <description>The study physician made a global assessment of the participant's response to treatment on a 5-point Likert scale (Very good, Good, Fair, Poor, Very poor) at Days 15, 29, 57, 85, 113, and 141. The category 'Not assessed' includes missing data and 'not done'. The number of participants in each of the 5 categories of the Likert scale are reported.</description>
          <population>Full Analysis Set (FAS): All patients as randomized that had at least 1 post-baseline assessment of the primary efficacy variable. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned at randomization.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15: Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 - Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 - Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 - Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 - Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29- Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57: Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57- Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 - Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 - Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 - Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85: Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="29"/>
                    <measurement group_id="O7" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 - Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 - Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 - - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 - Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 - Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 : Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 - Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 - Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 - Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 - Not Assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 : Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 - Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 - Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 - Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 - Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 - Not Assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Participant's Assessment of Gout Pain on a 100 mm Visual Analog Scale During the First Flare</title>
        <description>Participant's rated the intensity of pain in the most affected joint during the first flare on a 0-100 mm visual analog scale, which ranged from no pain (left end, 0) to unbearable pain (right end, 100). Assessments were made pre-dose and 24 hours, 3 days, 4 days, and an average of 5-7 days post-dose</description>
        <time_frame>Baseline of the extension study until 7 days after the onset of the first gout flare (up to 24 weeks)</time_frame>
        <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: Group A</title>
            <description>Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Extension Study: Group C</title>
            <description>Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Participant's Assessment of Gout Pain on a 100 mm Visual Analog Scale During the First Flare</title>
          <description>Participant's rated the intensity of pain in the most affected joint during the first flare on a 0-100 mm visual analog scale, which ranged from no pain (left end, 0) to unbearable pain (right end, 100). Assessments were made pre-dose and 24 hours, 3 days, 4 days, and an average of 5-7 days post-dose</description>
          <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose (n=65, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" spread="27.13"/>
                    <measurement group_id="O2" value="71.8" spread="20.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours (n=65, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="23.32"/>
                    <measurement group_id="O2" value="29.0" spread="22.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 days (n=54, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="16.82"/>
                    <measurement group_id="O2" value="6.8" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 days (n=54, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="14.32"/>
                    <measurement group_id="O2" value="2.7" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-7 days (n=52, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="15.86"/>
                    <measurement group_id="O2" value="2.1" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Participant's Global Assessment of Response to Treatment on a 5-point Likert Scale</title>
        <description>Study participants made a global assessment of their response to treatment on a 5-point Likert scale (Excellent, Good, Acceptable, Slight, Poor) at the control visit 7±2 days following each of their first 3 flares. The number of participants in each of the 5 categories of the Likert scale are reported.</description>
        <time_frame>Baseline of the extension study until the end of the study (up to 24 weeks)</time_frame>
        <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: Group A</title>
            <description>Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Extension Study: Group C</title>
            <description>Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Participant's Global Assessment of Response to Treatment on a 5-point Likert Scale</title>
          <description>Study participants made a global assessment of their response to treatment on a 5-point Likert scale (Excellent, Good, Acceptable, Slight, Poor) at the control visit 7±2 days following each of their first 3 flares. The number of participants in each of the 5 categories of the Likert scale are reported.</description>
          <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gout Flare 1: Excellent (63, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 1: Good (63, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 1: Acceptable (63, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 1: Slight (63, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 1: Poor (63, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Excellent (11, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Good (11, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Acceptable (11, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Slight (11, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Poor (11, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Excellent (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Good (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Acceptable (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Slight (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Poor (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Physician's Global Assessment of Response to Treatment on a 5-point Likert Scale</title>
        <description>The study physician made a global assessment of the participant's response to treatment on a 5-point Likert scale (Very good, Good, Fair, Poor, Very poor) at the control visit 7±2 days following each of the first 3 flares. The category 'Not assessed' includes missing data and 'not done'. The number of participants in each of the 5 categories of the Likert scale are reported.</description>
        <time_frame>Baseline of the extension study until the end of the study (up to 24 weeks)</time_frame>
        <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: Group A</title>
            <description>Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Extension Study: Group C</title>
            <description>Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Physician's Global Assessment of Response to Treatment on a 5-point Likert Scale</title>
          <description>The study physician made a global assessment of the participant's response to treatment on a 5-point Likert scale (Very good, Good, Fair, Poor, Very poor) at the control visit 7±2 days following each of the first 3 flares. The category 'Not assessed' includes missing data and 'not done'. The number of participants in each of the 5 categories of the Likert scale are reported.</description>
          <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gout Flare 1: Very Good (69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 1: Good (69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 1: Fair (69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 1: Poor (69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 1: Very Poor (69, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Very Good (12, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Good (12, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Fair (12, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Poor (12, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Very Poor (12, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Very Good (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Good (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Fair (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Poor (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Very Poor (3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Physician's Assessment of Tenderness, Swelling, and Erythema in the Most Affected Joint During the First Flare</title>
        <description>Tenderness was rated on a 0-3 point scale: 0=&quot;no pain&quot;, 1=patient states that &quot;there is pain&quot;, 2=patient states &quot;there is pain and winces&quot;, and 3=patient states &quot;there is pain, winces and withdraws&quot; on palpation or passive movement of the most affected joint. Swelling was rated on a 0-3 point scale: 0=&quot;no swelling&quot;, 1=&quot;palpable&quot;, 2=&quot;visible&quot;, and 3=bulging beyond the joint margins&quot;. Erythema was rated as present, absent, or not assessable. Assessments were performed at the flare and control visits.</description>
        <time_frame>Baseline of the extension study until the end of the study (up to 24 weeks)</time_frame>
        <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: Group A</title>
            <description>Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Extension Study: Group C</title>
            <description>Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Physician's Assessment of Tenderness, Swelling, and Erythema in the Most Affected Joint During the First Flare</title>
          <description>Tenderness was rated on a 0-3 point scale: 0=&quot;no pain&quot;, 1=patient states that &quot;there is pain&quot;, 2=patient states &quot;there is pain and winces&quot;, and 3=patient states &quot;there is pain, winces and withdraws&quot; on palpation or passive movement of the most affected joint. Swelling was rated on a 0-3 point scale: 0=&quot;no swelling&quot;, 1=&quot;palpable&quot;, 2=&quot;visible&quot;, and 3=bulging beyond the joint margins&quot;. Erythema was rated as present, absent, or not assessable. Assessments were performed at the flare and control visits.</description>
          <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness Flare Visit: No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Flare Visit: Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Flare Visit: Pain and winces</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Flare Visit: Pain, winces and withdraws</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Control Visit: No pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Control Visit: Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Control Visit: Pain and winces</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Control Visit: Pain, winces and withdra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Swelling Flare Visit: No swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Swelling Flare Visit: Palpable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Swelling Flare Visit: Visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Swelling Flare Visit: Bulging beyond joint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Swelling Control Visit: No swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Swelling Control Visit: Palpable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Swelling Control Visit: Visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Swelling Control Visit: Bulging beyond joint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Flare Visit: Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Flare Visit: Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Flare Visit: Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Control Visit: Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Control Visit: Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Control Visit: Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Study: Amount of Rescue Medication Taken</title>
        <description>The amount of naproxen and prednisolone taken after receiving treatment for each of the first 3 flares was recorded.</description>
        <time_frame>Baseline of the extension study until the end of the study (up to 24 weeks)</time_frame>
        <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Study: Group A</title>
            <description>Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Extension Study: Group C</title>
            <description>Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Study: Amount of Rescue Medication Taken</title>
          <description>The amount of naproxen and prednisolone taken after receiving treatment for each of the first 3 flares was recorded.</description>
          <population>Efficacy set: All Group A and C participants who received at least 1 dose of canakinumab during the extension study.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gout Flare 1: Naproxen (n=68, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1086.8" spread="1592.72"/>
                    <measurement group_id="O2" value="954.6" spread="1130.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 1: Prednisolone (68, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="20.84"/>
                    <measurement group_id="O2" value="4.2" spread="20.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Naproxen (n=12, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.0" spread="642.79"/>
                    <measurement group_id="O2" value="200.0" spread="447.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 2: Prednisolone (12, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.11"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Naproxen (n=4, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.0" spread="500.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gout Flare 3: Prednisolone (4, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Core Study: ACZ 25 mg</title>
          <description>Core study: ACZ 25 mg</description>
        </group>
        <group group_id="E2">
          <title>Core Study: ACZ 50 mg</title>
          <description>Core study: ACZ 50 mg</description>
        </group>
        <group group_id="E3">
          <title>Core Study: ACZ 100 mg</title>
          <description>Core study: ACZ 100 mg</description>
        </group>
        <group group_id="E4">
          <title>Core Study: ACZ 200 mg</title>
          <description>Core study: ACZ 200 mg</description>
        </group>
        <group group_id="E5">
          <title>Core Study: ACZ 300 mg</title>
          <description>Core study: ACZ 300 mg</description>
        </group>
        <group group_id="E6">
          <title>Core Study: ACZ Q4wk mg</title>
          <description>Core study: ACZ Q4wk mg</description>
        </group>
        <group group_id="E7">
          <title>Core Study: Colch 0.5 mg</title>
          <description>Core study: Colch 0.5 mg</description>
        </group>
        <group group_id="E8">
          <title>Extension Study: Group A</title>
          <description>Extension study: Group A</description>
        </group>
        <group group_id="E9">
          <title>Extension Study: Group B</title>
          <description>Extension study: Group B</description>
        </group>
        <group group_id="E10">
          <title>Extension Study: Group C</title>
          <description>Extension study: Group C</description>
        </group>
        <group group_id="E11">
          <title>Extension Study: Group D</title>
          <description>Extension study: Group D</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gouty tophus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

